Archives: 2021-11-12

Study reveals tactics used by US stem cell clinics to market their treatments

Stem cell clinics continue to thrive in the US and worldwide, building their business on misleading advertising and offering unapproved and unproven stem-cell-based interventions (SCBI). A research recently published in Stem Cell Reports by Emma Frow, David Brafman, and colleagues from Arizona State University, asked what kinds of claims and evidence these clinics use to market their

Read More


Covid-19 vaccines protection against hospitalization and ICU effectiveness dropping over time: results in different studies

As millions of eligible people consider getting a booster shot, many are wondering what the data tells us about the effectiveness of the vaccines, and how much their protection might be waning. The good news is that a growing body of research shows that the vaccines authorized remain highly protective against severe disease and hospitalization

Read More


SARS-CoV-2 uses sugars to invade human cells, new study by University of Alberta shows

Understanding the process could help scientists look out for new, more infectious variants. Sugars found on the surface of human cells influence COVID-19 infection, according to a University of Alberta-led study that is one of the first to observe this relationship and suggests that cells in the brain might be particularly susceptible. “The idea here is that

Read More


Novel mesenchymal stem cell therapy approach proves effective in treating COVID-19

An international team of researchers has advanced a new therapeutic approach using stem cells to treat COVID-19. Despite many advances in treating the COVID-19 virus there remains no specific cure for patients with infection. This is especially the case with hospitalised patients who end up in the ICU requiring mechanical ventilation support. Key members of

Read More


Cell therapies, Gene therapy and CAR-T cells highlighted in EFPIA Pipeline Review 2021 Update

The new EFPIA Pipeline Review reveals that infectious, inflammatory, cancer, Alzheimer’s and rare disesases areas are among the top priorities of researchers running clinical trials today to investigate new medicines and vaccines. The comprehensive report found that in 2020 alone, around 5,000 clinical trials were launched – despite the disruption caused by the COVID-19 pandemic. In fact, the volume of trials has

Read More


A prospective cohort study on the long term effects of COVID-19: new disability, functional outcomes and return to work at 6 months

A recent Monash University study has found six months after recovering from COVID-19 critical illness, one in five people had died, and almost 40 per cent of survivors had a new disability. Led by Professor Carol Hodgson, the study looked at COVID-19 critical illness across Australia between March 6 and October 4, 2020, measuring mortality, new

Read More


BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age evaluation paper published in NEJM

Safe, effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in children younger than 12 years of age. A phase 1, dose-finding study and an ongoing phase 2–3 randomized trial are being conducted to investigate the safety, immunogenicity, and efficacy of two doses of the BNT162b2 vaccine administered 21 days apart in children 6

Read More


Ernst & Young white paper details how the Cell Gene Therapy industry can collaborate to advance the field

Harnessing the power of cell and gene therapies will require a next-generation level of collaboration not seen before the COVID-19 pandemic. In brief Before cell and gene therapies can meet increasing demand at the necessary speed and scale, the industry must address key challenges. A fractured supply chain, complicated manufacturing and unprecedented pricing are among

Read More


Pfizer’s novel COVID-19 oral antiviral protease inhibitor reduced risk of hospitalization or death by 89% in interm analysis of Phase 2/3 EPIC-HR study

PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with COVID-19 In the overall study population through Day 28, no deaths were reported in patients who received PAXLOVID™ as compared to 10 deaths in patients who received placebo Pfizer plans to submit the data as

Read More